Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study

Maribavir, an orally bioavailable antiviral, has shown superior activity against posttransplant cytomegalovirus infection compared with conventional antivirals. It is primarily metabolized in the liver. This open‐label, single‐center study evaluated the effect of hepatic impairment on the pharmacoki...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ivy, Chen, Grace, Wu, Jingyang, Ilic, Katarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091977/
https://www.ncbi.nlm.nih.gov/pubmed/36089648
http://dx.doi.org/10.1002/jcph.2155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091977/
https://www.ncbi.nlm.nih.gov/pubmed/36089648
http://dx.doi.org/10.1002/jcph.2155

Ejemplares similares